{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:35:49Z","timestamp":1781066149199,"version":"3.54.1"},"reference-count":34,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"\n Background & objectives<\/jats:title>\n \n Non-alcoholic fatty liver disease (NAFLD) is considered as the most prevalent chronic metabolic disease, characterised by steatosis, inflammation, and metabolic dysfunctions with impaired functions of liver enzymes. The fat mass and obesity-associated gene (\n FTO<\/jats:italic>\n ) plays an important role in fat accumulation in hepatocytes. We investigated how FTO regulated the expression of its target genes\n via<\/jats:italic>\n m6A modification leading to the pathophysiology of NAFLD.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A NAFLD mouse model was developed by feeding C57Bl\/6 male mice on high-fat, high-carbohydrate (HFHC) diet supplemented with fructose and sucrose up to 24 wk. Changes in the liver histology were examined in serial sections by microscopy and immunohistochemistry, the serum parameters were monitored by bioanalyser and ELISA. Expression of hepatic murine FTO (mFTO) and metabolic gene transcripts were quantified by qPCR and mRNA sequencing. mFTO protein expression was analysed by immunohistochemistry and western blotting.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The NAFLD mouse model developed steatosis, inflammation, and fibrosis at 19-24 wk, along with elevated liver enzyme levels, altered lipid profiles, and increased mFTO expression. Transcriptomic analysis identified differentially expressed genes and pathways associated with NAFLD progression. Pharmacological inhibition of mFTO by entacapone restored m6A marks on gene transcripts and reversed the NAFLD phenotype.<\/jats:p>\n <\/jats:sec>\n \n Interpretation & conclusions<\/jats:title>\n Gene expression profiling identified key metabolic pathways and molecular targets associated with NAFLD progression. It underscored the role of mFTO in altering the m6A methylation landscape essential for establishing NAFLD and highlighted its therapeutic potential for NAFLD-associated morbidities.<\/jats:p>\n <\/jats:sec>","DOI":"10.25259\/ijmr_945_2025","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:18:15Z","timestamp":1762946295000},"page":"380-388","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Epigenetic regulation of NAFLD: A preclinical study"],"prefix":"10.25259","volume":"162","author":[{"given":"Sunita","family":"Giri","sequence":"first","affiliation":[{"name":"Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupma Kumari","family":"Parasar","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"10.25259\/IJMR_945_2025\/ref-1","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Non-alcoholic fatty liver disease 2020: The state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"10.25259\/IJMR_945_2025\/ref-2","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of non-alcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.25259\/IJMR_945_2025\/ref-3","doi-asserted-by":"publisher","first-page":"103043","DOI":"10.1016\/j.arcmed.2024.103043","article-title":"Global prevalence of nonalcoholic fatty liver disease: An updated review meta-analysis comprising a population of 78 million from 38 countries","volume":"55","author":"Amini-Salehi","year":"2024","journal-title":"Arch Med Res"},{"key":"10.25259\/IJMR_945_2025\/ref-4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1146\/annurev-med-042220-020407","article-title":"Fatty liver disease: Diagnosis and stratification","volume":"73","author":"Saiman","year":"2022","journal-title":"Annu Rev Med"},{"key":"10.25259\/IJMR_945_2025\/ref-5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.25259\/IJMR_945_2025\/ref-6","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.25259\/IJMR_945_2025\/ref-7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.25259\/IJMR_945_2025\/ref-8","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.25259\/IJMR_945_2025\/ref-9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: Clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"key":"10.25259\/IJMR_945_2025\/ref-10","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.tem.2023.09.002","article-title":"N6-methyladenosine RNA modification in nonalcoholic fatty liver disease","volume":"34","author":"Luo","year":"2023","journal-title":"Trends Endocrinol Metab"},{"key":"10.25259\/IJMR_945_2025\/ref-11","doi-asserted-by":"publisher","first-page":"e0046","DOI":"10.1097\/HC9.0000000000000046","article-title":"Roles of RNA m6A modification in nonalcoholic fatty liver disease","volume":"7","author":"Tan","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.25259\/IJMR_945_2025\/ref-12","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1126\/science.1151710","article-title":"The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase","volume":"318","author":"Gerken","year":"2007","journal-title":"Science"},{"key":"10.25259\/IJMR_945_2025\/ref-13","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1016\/j.gendis.2022.04.014","article-title":"Studies on the fat mass and obesity-associated (FTO) gene and its impact on obesity-associated diseases","volume":"10","author":"Huang","year":"2022","journal-title":"Genes Dis"},{"key":"10.25259\/IJMR_945_2025\/ref-14","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.3390\/cells10071805","article-title":"Diet-induced models of non-alcoholic fatty liver disease: Food for thought on sugar, fat, and cholesterol","volume":"10","author":"Eng","year":"2021","journal-title":"Cells"},{"key":"10.25259\/IJMR_945_2025\/ref-15","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.7150\/ijbs.65044","article-title":"Mouse models of nonalcoholic fatty liver disease (NAFLD): Pathomechanisms and pharmacotherapies","volume":"18","author":"Fang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"10.25259\/IJMR_945_2025\/ref-16","doi-asserted-by":"publisher","first-page":"15791","DOI":"10.3390\/ijms232415791","article-title":"Genetic and diet-induced animal models for non-alcoholic fatty liver disease (NAFLD) research","volume":"23","author":"Flessa","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.25259\/IJMR_945_2025\/ref-17","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.25259\/IJMR_945_2025\/ref-18","doi-asserted-by":"publisher","first-page":"109766","DOI":"10.1016\/j.cellsig.2020.109766","article-title":"Ubiquitin ligase TRUSS augments the expression of interleukin-10 via proteasomal processing of NF-\u03baB1\/p105 to NF-\u03baB\/p50","volume":"75","author":"Jamal","year":"2020","journal-title":"Cell Signal"},{"key":"10.25259\/IJMR_945_2025\/ref-19","doi-asserted-by":"publisher","first-page":"D380","DOI":"10.1093\/nar\/gkx1013","article-title":"TRRUST v2: An expanded reference database of human and mouse transcriptional regulatory interactions","volume":"46","author":"Han","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.25259\/IJMR_945_2025\/ref-20","doi-asserted-by":"publisher","first-page":"101257","DOI":"10.1016\/j.molmet.2021.101257","article-title":"Phosphoenolpyruvate carboxy kinase in cell metabolism: Roles and mechanisms beyond gluconeogenesis","volume":"53","author":"Yu","year":"2021","journal-title":"Mol Metab"},{"key":"10.25259\/IJMR_945_2025\/ref-21","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3389\/fendo.2018.00802","article-title":"Unraveling the regulation of hepatic gluconeogenesis","volume":"9","author":"Zhang","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.25259\/IJMR_945_2025\/ref-22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s1534-5807(02)00401-x","article-title":"The forkhead transcription factor foxo1 regulates adipocyte differentiation","volume":"4","author":"Nakae","year":"2003","journal-title":"Dev Cell"},{"key":"10.25259\/IJMR_945_2025\/ref-23","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1016\/S0021-9258(18)89132-3","article-title":"Sterol carrier protein 2 and fatty acid-binding protein separate and distinct physiological functions","volume":"260","author":"Scallen","year":"1985","journal-title":"J Biol Chem"},{"key":"10.25259\/IJMR_945_2025\/ref-24","doi-asserted-by":"publisher","first-page":"624112","DOI":"10.3389\/fendo.2021.624112","article-title":"PPAR gamma in metabolism, immunity, and cancer: Unified and diverse mechanisms of action","volume":"12","author":"Hernandez-Quiles","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.25259\/IJMR_945_2025\/ref-25","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1016\/j.ymthe.2022.02.021","article-title":"Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma","volume":"30","author":"Yang","year":"2022","journal-title":"Mol Ther"},{"key":"10.25259\/IJMR_945_2025\/ref-26","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/00071668.2016.1201199","article-title":"Hepatic expression of FTO and fatty acid metabolic genes changes in response to lipopolysaccharide with alterations in m6A modification of relevant mRNAs in the chicken","volume":"57","author":"Zhang","year":"2016","journal-title":"Br Poult Sci"},{"key":"10.25259\/IJMR_945_2025\/ref-27","doi-asserted-by":"publisher","first-page":"eaau7116","DOI":"10.1126\/scitranslmed.aau7116","article-title":"Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1","volume":"11","author":"Peng","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.25259\/IJMR_945_2025\/ref-28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12944-022-01640-y","article-title":"Fat mass and obesity-associated protein promotes liver steatosis by targeting PPAR\u03b1","volume":"21","author":"Wei","year":"2022","journal-title":"Lipids Health Dis"},{"key":"10.25259\/IJMR_945_2025\/ref-29","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.bbalip.2018.02.003","article-title":"FTO promotes SREBP1c maturation and enhances CIDEC transcription during lipid accumulation in HepG2 cells","volume":"1863","author":"Chen","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.25259\/IJMR_945_2025\/ref-30","doi-asserted-by":"publisher","first-page":"6792","DOI":"10.1038\/ncomms7792","article-title":"FTO influences adipogenesis by regulating mitotic clonal expansion","volume":"6","author":"Merkestein","year":"2015","journal-title":"Nat Commun"},{"key":"10.25259\/IJMR_945_2025\/ref-31","doi-asserted-by":"publisher","first-page":"101428","DOI":"10.1016\/j.molmet.2021.101428","article-title":"CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing","volume":"57","author":"Zeng","year":"2022","journal-title":"Mol Metab"},{"key":"10.25259\/IJMR_945_2025\/ref-32","doi-asserted-by":"publisher","first-page":"eaba4448","DOI":"10.1126\/scitranslmed.aba4448","article-title":"Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis","volume":"12","author":"Govaere","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.25259\/IJMR_945_2025\/ref-33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2174\/1566524020666201026162343","article-title":"Critical role of NF\u03baB in the pathogenesis of non-alcoholic fatty liver disease: a widespread key regulator","volume":"21","author":"Franceschetti","year":"2021","journal-title":"Curr Mol Med"},{"key":"10.25259\/IJMR_945_2025\/ref-34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12967-024-05084-z","article-title":"The role of DGAT1 and DGAT2 in regulating tumor cell growth and their potential clinical implications","volume":"22","author":"Deng","year":"2024","journal-title":"J Transl Med"}],"container-title":["The Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/epigenetic-regulation-of-nafld-a-preclinical-study\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/epigenetic-regulation-of-nafld-a-preclinical-study\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:18:16Z","timestamp":1762946296000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/epigenetic-regulation-of-nafld-a-preclinical-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":34,"alternative-id":["10.25259\/IJMR_945_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_945_2025","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"article-number":"380"}}